---
figid: PMC7463546__cancers-12-02203-g001
figtitle: NFKB signaling pathway and anti-multiple myeloma (MM) drug targets
organisms:
- Homo sapiens
- Mus musculus
- Canis lupus familiaris
- Rheum rhabarbarum
pmcid: PMC7463546
filename: cancers-12-02203-g001.jpg
figlink: pmc/articles/PMC7463546/figure/cancers-12-02203-f001/
number: F1
caption: Schematic diagram of the NF-κB signaling pathway and anti-multiple myeloma
  (MM) drug targets. First-line anti-MM drugs (highlighted in orange) passively target
  the canonical and/or non-canonical pathways to shut down NF-κB signaling. For example,
  bortezomib inhibits the 26S proteasome to hinder the processing of p105 and p100
  proteins, to prevent gene transcription activation in canonical and non-canonical
  NF-κB signaling pathways, respectively; dexamethasone induces IκB protein synthesis
  to inhibit p105 processing; lenalidomide reduces RelA binding to open chromatin;
  cyclophosphamide is a DNA alkylating agent that disrupts DNA replication and genome
  stability. Ligands, adaptor proteins and transcriptional complexes involved in canonical
  NF-κB signaling are depicted in dark blue, whereas those involved in non-canonical
  NF-κB signaling are depicted in light blue; kinases are depicted in green; inhibitors
  are depicted in red. P and Ub indicate the post-translational modifications of phosphorylation
  and ubiquitination, respectively. Arrows with triangle heads indicate activation,
  whereas arrows with rhomboid heads indicate inactivation/inhibition; direct interactions
  are indicated by solid lines, whereas indirect interactions are indicated by dash
  lines.
papertitle: Targeting NF-κB Signaling for Multiple Myeloma.
reftext: Ada Hang-Heng Wong, et al. Cancers (Basel). 2020 Aug;12(8):2203.
year: '2020'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9361643
figid_alias: PMC7463546__F1
figtype: Figure
organisms_ner:
- Homo sapiens
- Mus musculus
- Canis lupus familiaris
redirect_from: /figures/PMC7463546__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7463546__cancers-12-02203-g001.html
  '@type': Dataset
  description: Schematic diagram of the NF-κB signaling pathway and anti-multiple
    myeloma (MM) drug targets. First-line anti-MM drugs (highlighted in orange) passively
    target the canonical and/or non-canonical pathways to shut down NF-κB signaling.
    For example, bortezomib inhibits the 26S proteasome to hinder the processing of
    p105 and p100 proteins, to prevent gene transcription activation in canonical
    and non-canonical NF-κB signaling pathways, respectively; dexamethasone induces
    IκB protein synthesis to inhibit p105 processing; lenalidomide reduces RelA binding
    to open chromatin; cyclophosphamide is a DNA alkylating agent that disrupts DNA
    replication and genome stability. Ligands, adaptor proteins and transcriptional
    complexes involved in canonical NF-κB signaling are depicted in dark blue, whereas
    those involved in non-canonical NF-κB signaling are depicted in light blue; kinases
    are depicted in green; inhibitors are depicted in red. P and Ub indicate the post-translational
    modifications of phosphorylation and ubiquitination, respectively. Arrows with
    triangle heads indicate activation, whereas arrows with rhomboid heads indicate
    inactivation/inhibition; direct interactions are indicated by solid lines, whereas
    indirect interactions are indicated by dash lines.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - IL1B
  - TNFSF11
  - CD40LG
  - TNF
  - LTBR
  - TNFRSF11A
  - EGF
  - IL1R1
  - TNFSF13B
  - CD40
  - TNFRSF1A
  - EGFR
  - TRAF2
  - TANK
  - TNFRSF13C
  - TRAF6
  - TRAF3
  - TRAF5
  - CHUK
  - MAP3K14
  - MAP4K4
  - IKBKB
  - IKBKG
  - CDH13
  - SCYL1
  - IKBKE
  - TBK1
  - RELA
  - CUX1
  - NFKB2
  - OAS3
  - PMEL
  - SART3
  - TPX2
  - SND1
  - ASCC2
  - RELB
  - PSMA1
  - PSMA2
  - PSMA3
  - PSMA4
  - PSMA5
  - PSMA6
  - PSMA7
  - PSMA8
  - PSMB1
  - PSMB10
  - PSMB2
  - PSMB3
  - PSMB4
  - PSMB5
  - PSMB6
  - PSMB7
  - PSMB8
  - PSMB9
  - PSMC1
  - PSMC2
  - PSMC3
  - PSMC4
  - PSMC5
  - PSMC6
  - PSMD1
  - PSMD10
  - PSMD11
  - PSMD12
  - PSMD13
  - PSMD14
  - PSMD2
  - PSMD3
  - PSMD4
  - PSMD5
  - PSMD6
  - PSMD7
  - PSMD8
  - PSMD9
  - PSME1
  - PSME2
  - PSME3
  - PSMF1
  - SEM1
  - USP5
  - ARHGEF7
  - ASCC1
  - H3P40
  - FKBP4
  - GTF2H4
  - PMPCB
  - PSIP1
  - H3P42
  - H1-0
  - H1-1
  - H1-2
  - H1-3
  - H1-4
  - H1-5
  - H1-6
  - H1-7
  - H1-8
  - H1-10
  - .na.character
  - H2AB1
  - H2AJ
  - H2AZ2
  - H2AX
  - MACROH2A1
  - MACROH2A2
  - H2AZ1
  - H2AC1
  - H2AC6
  - H2AC7
  - H2AC12
  - H2AC14
  - H2AC21
  - H2AC20
  - H2AC25
  - H2BC1
  - H2BC3
  - H2BC5
  - H2BC9
  - H2BC11
  - H2BC12
  - H2BC13
  - H2BC14
  - H2BC15
  - H2BC17
  - H2BC18
  - H2BC19P
  - H2BC20P
  - H2BC21
  - H2BC26
  - H2BC12L
  - H2BW2
  - H2BW1
  - H3-4
  - H3-5
  - H4C7
  - Il1
  - Tnfsf11
  - Cd40lg
  - Tnf
  - Ltbr
  - Tnfrsf11a
  - Egf
  - Tnfsf13b
  - Cd40
  - Tnfrsf1a
  - Egfr
  - Traf2
  - Tnfrsf13c
  - Traf6
  - Traf3
  - Traf5
  - Chuk
  - Map4k4
  - Map3k14
  - Ikbkb
  - Ikbkg
  - Nedd9
  - Nfkb1
  - Scyl1
  - Nfkbib
  - Rela
  - Tpx2
  - Relb
  - Cdc37
  - Lsp1
  - Pold2
  - Dctn2
  - Gtf2h4
  - Nfkb2
  - Igbp1
  - Dexamethasone
  - Prednisone
  - Bortezomib
  - Carfilzomib
  - Ixazomib
  - Aspirin
  - Lenalidomide
  - Polmalidomide
  - Thalidomide
  - Cyclophosphamide
  - Doxorubicin
  - Melphalan
  - Bendamustine
  - Cisplatin
  - Etoposide
  - CIAPS
---
